{"id":131027,"date":"2026-06-25T12:48:54","date_gmt":"2026-06-25T07:18:54","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=131027"},"modified":"2026-06-25T12:48:56","modified_gmt":"2026-06-25T07:18:56","slug":"aurobindo-pharma-latest-news-52-week-high-june-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/","title":{"rendered":"Aurobindo Pharma Latest News: Aurobindo Pharma Scales 52-Week High of Rs 1,559 Backed by Strong Fundamentals"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Aurobindo Pharma latest news: NSE: AUROPHARMA Rs 1,559 (latest). 52W high Rs 1,559. 52W low Rs 1,016.10. MCap Rs ~91,700 Cr. P\/E 23.70x. 1Y gain from low: +~53%.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/auropharm\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma<\/a> Latest News is in focus as <a href=\"https:\/\/univest.in\/stocks\/auropharma\/aurobindo-pharma-ltd-share-price-today\">Aurobindo Pharma Ltd (NSE: AUROPHARMA)<\/a> hit a 52-week high of Rs 1,559 today, extending a strong rally that has delivered ~53% returns from its 52-week low of Rs 1,016.10. The Pharmaceuticals company is backed by strong fundamentals and key business developments driving the Aurobindo Pharma latest news rally.<\/p>\n<p>This Aurobindo Pharma latest news analysis covers the key catalysts behind the 52-week high, what market analysts are observing, the next price targets and levels to watch, and the key risks investors should monitor.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=aurobindo-pharma-latest-news-52-week-hig\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#About_Aurobindo_Pharma_Company_Overview\" title=\"About Aurobindo Pharma: Company Overview\">About Aurobindo Pharma: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#What_Is_Driving_the_Aurobindo_Pharma_Latest_News_52-Week_High_Key_Reasons\" title=\"What Is Driving the Aurobindo Pharma Latest News 52-Week High? Key Reasons\">What Is Driving the Aurobindo Pharma Latest News 52-Week High? Key Reasons<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Q4_FY26_Revenue_Rs_8751_Crore_with_US_Injectables_Up_17_Year-on-Year\" title=\"Q4 FY26 Revenue Rs 8,751 Crore with US Injectables Up 17% Year-on-Year\">Q4 FY26 Revenue Rs 8,751 Crore with US Injectables Up 17% Year-on-Year<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#CDSCO_Approves_Bevqolva_First_Indian_Biosimilar_Bevacizumab\" title=\"CDSCO Approves Bevqolva: First Indian Biosimilar Bevacizumab\">CDSCO Approves Bevqolva: First Indian Biosimilar Bevacizumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#European_Market_Performance_Up_84_and_Healthy_Pipeline_Ahead\" title=\"European Market Performance Up 8.4% and Healthy Pipeline Ahead\">European Market Performance Up 8.4% and Healthy Pipeline Ahead<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#What_Market_Analysts_Are_Saying_About_Aurobindo_Pharma_Latest_News\" title=\"What Market Analysts Are Saying About Aurobindo Pharma Latest News\">What Market Analysts Are Saying About Aurobindo Pharma Latest News<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Aurobindo_Pharma_Latest_News_Next_Share_Price_Targets_and_Key_Levels\" title=\"Aurobindo Pharma Latest News: Next Share Price Targets and Key Levels\">Aurobindo Pharma Latest News: Next Share Price Targets and Key Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Key_Risks_to_Monitor\" title=\"Key Risks to Monitor\">Key Risks to Monitor<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#USFDA_Inspection_and_Warning_Letter_Risk\" title=\"USFDA Inspection and Warning Letter Risk\">USFDA Inspection and Warning Letter Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Pricing_Pressure_in_US_Generics_Market\" title=\"Pricing Pressure in US Generics Market\">Pricing Pressure in US Generics Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Currency_Risk_from_USD_and_EUR_Exposure\" title=\"Currency Risk from USD and EUR Exposure\">Currency Risk from USD and EUR Exposure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Frequently_Asked_Questions_on_Aurobindo_Pharma_Latest_News\" title=\"Frequently Asked Questions on Aurobindo Pharma Latest News\">Frequently Asked Questions on Aurobindo Pharma Latest News<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#What_is_Aurobindo_Pharma_latest_news_today\" title=\"What is Aurobindo Pharma latest news today?\">What is Aurobindo Pharma latest news today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Why_is_Aurobindo_Pharma_at_52-week_high\" title=\"Why is Aurobindo Pharma at 52-week high?\">Why is Aurobindo Pharma at 52-week high?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#What_is_the_Bevqolva_approval_for_Aurobindo_Pharma\" title=\"What is the Bevqolva approval for Aurobindo Pharma?\">What is the Bevqolva approval for Aurobindo Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#What_is_Aurobindo_Pharmas_valuation_versus_Nifty_Pharma_peers\" title=\"What is Aurobindo Pharma&#8217;s valuation versus Nifty Pharma peers?\">What is Aurobindo Pharma&#8217;s valuation versus Nifty Pharma peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#What_is_Aurobindo_Pharmas_market_cap_and_valuation_at_the_52-week_high\" title=\"What is Aurobindo Pharma&#8217;s market cap and valuation at the 52-week high?\">What is Aurobindo Pharma&#8217;s market cap and valuation at the 52-week high?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-latest-news-52-week-high-june-2026\/#Is_Aurobindo_Pharma_a_buy_at_the_52-week_high\" title=\"Is Aurobindo Pharma a buy at the 52-week high?\">Is Aurobindo Pharma a buy at the 52-week high?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Aurobindo_Pharma_Company_Overview\"><\/span><strong>About Aurobindo Pharma: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>One of India&#8217;s top pharma exporters and a global leader in US generics, with a diversified portfolio spanning finished dosage formulations, APIs, biosimilars, and injectables. Aurobindo serves over 150 countries through 36 manufacturing facilities and holds over 600 USFDA product approvals. Key growth drivers include US injectable scale-up, biosimilar launches (Bevqolva approved for cancer treatment), and the ramp-up of the Pen-G penicillin facility.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px; margin: 12px 0;\">\n<tbody>\n<tr style=\"background: #1F3864; color: #ffffff;\">\n<th style=\"padding: 8px; text-align: left;\">Metric<\/th>\n<th style=\"padding: 8px; text-align: left;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">CMP (Latest)<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Rs 1,559<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FA;\">\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">52-Week High<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Rs 1,559<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">52-Week Low<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Rs 1,016.10<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FA;\">\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Market Cap<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Rs ~91,700 Cr<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">P\/E Ratio (TTM)<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">23.70x<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FA;\">\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Sector<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">1-Year Return from Low<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">+~53%<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FA;\">\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">NSE Symbol<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">NSE: AUROPHARMA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_the_Aurobindo_Pharma_Latest_News_52-Week_High_Key_Reasons\"><\/span><strong>What Is Driving the Aurobindo Pharma Latest News 52-Week High? Key Reasons<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three key developments have powered the Aurobindo Pharma latest news stock to a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q4_FY26_Revenue_Rs_8751_Crore_with_US_Injectables_Up_17_Year-on-Year\"><\/span><strong>Q4 FY26 Revenue Rs 8,751 Crore with US Injectables Up 17% Year-on-Year<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aurobindo Pharma&#8217;s Q4 FY26 consolidated revenue grew 4.42% to Rs 8,751 crore with net profit of Rs 921.26 crore (+1.97% year-on-year). The US business, which accounts for approximately 40% of revenue, saw injectable sales grow 17% year-on-year, the fastest-growing product segment. The Pen-G facility ramp-up is expected to contribute meaningfully to margins in FY27 as utilisation increases.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"CDSCO_Approves_Bevqolva_First_Indian_Biosimilar_Bevacizumab\"><\/span><strong>CDSCO Approves Bevqolva: First Indian Biosimilar Bevacizumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aurobindo Pharma&#8217;s biosimilar subsidiary CuraTeQ Biologics received Central Drugs Standard Control Organisation (CDSCO) marketing authorisation for Bevqolva, a bevacizumab biosimilar used in cancer treatment. This is a significant milestone in Aurobindo&#8217;s biosimilar strategy, which targets large-molecule opportunities beyond its traditional small-molecule generics business. Biosimilars typically command higher margins and pricing stability compared to commodity generics.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"European_Market_Performance_Up_84_and_Healthy_Pipeline_Ahead\"><\/span><strong>European Market Performance Up 8.4% and Healthy Pipeline Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aurobindo&#8217;s European formulation business demonstrated robust growth, contributing to the 8.4% year-on-year revenue increase in recent quarters. The company has a strong pipeline of complex generics, injectables, and biosimilars pending USFDA and EMA approvals. Analyst Ajit Mishra of Ventura Securities has recommended Aurobindo Pharma as a Buy based on the pharma sector&#8217;s current strength and the company&#8217;s multi-vertical growth strategy.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to Track Live Price and Key Fundamentals<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Market_Analysts_Are_Saying_About_Aurobindo_Pharma_Latest_News\"><\/span><strong>What Market Analysts Are Saying About Aurobindo Pharma Latest News<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma trades at a relatively moderate P\/E of 23.70x compared to Nifty Pharma index peers, making it one of the better-value large-cap pharma options in India. Market analysts broadly maintain a positive view on Aurobindo given its diversified revenue mix, strong US generics position, and the biosimilar pipeline. The Bevqolva approval is the most notable near-term catalyst, representing Aurobindo&#8217;s entry into the high-margin large-molecule pharmaceutical market.<\/p>\n<p>Ankit Jaiswal, Senior Research Analyst at Univest, notes that the Aurobindo Pharma latest news 52-week high is supported by genuine fundamental strength and the stock&#8217;s technical structure is bullish across all major moving average timeframes. He cautions that new positions at the 52-week high carry short-term correction risk and recommends waiting for consolidation above Rs 1,350 before initiating fresh positions.<\/p>\n<p>Kunal Singla, Research Analyst at Univest, observes that as long as the Aurobindo Pharma latest news stock holds above Rs 1,350 on weekly closes, the bullish trend structure remains intact and the Rs 1,700 to 1,900 zone is achievable over the coming weeks. He notes that the stock&#8217;s 52-week high breakout is technically significant and signals continued institutional accumulation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Latest_News_Next_Share_Price_Targets_and_Key_Levels\"><\/span><strong>Aurobindo Pharma Latest News: Next Share Price Targets and Key Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following the 52-week high, the key price levels for the Aurobindo Pharma latest news story are:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px; margin: 12px 0;\">\n<tbody>\n<tr style=\"background: #1F3864; color: #ffffff;\">\n<th style=\"padding: 8px; text-align: left;\">Level<\/th>\n<th style=\"padding: 8px; text-align: left;\">Price (Rs)<\/th>\n<th style=\"padding: 8px; text-align: left;\">Significance<\/th>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">52-Week High (Current)<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">1,559<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">New breakout level today<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FA;\">\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Near-Term Target<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">1,700 to 1,900<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Based on analyst views and technical momentum<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Key Support<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">1,350<\/td>\n<td style=\"padding: 8px; border-bottom: 1px solid #ddd;\">Weekly close support; hold here = trend intact<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>These levels are technical reference points and not guaranteed investment targets. Please consult a SEBI-registered financial advisor before making any investment decision in Aurobindo Pharma.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Monitor\"><\/span><strong>Key Risks to Monitor<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"USFDA_Inspection_and_Warning_Letter_Risk\"><\/span><strong>USFDA Inspection and Warning Letter Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aurobindo&#8217;s manufacturing facilities are subject to regular USFDA inspections. A data integrity observation or import alert on any major facility would directly impact US revenue, which accounts for approximately 40% of total revenue. The company has received inspection observations in the past, and regulatory risk remains one of the most significant overhang factors for the stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Pricing_Pressure_in_US_Generics_Market\"><\/span><strong>Pricing Pressure in US Generics Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The US generic drug market faces structural price erosion of 5 to 10% annually as more generic entrants compete for the same molecule. While Aurobindo benefits from being an early entrant in many products, sustained pricing pressure limits margin expansion unless offset by volume growth and new product launches.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Currency_Risk_from_USD_and_EUR_Exposure\"><\/span><strong>Currency Risk from USD and EUR Exposure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Aurobindo&#8217;s revenues are primarily denominated in USD (US sales) and EUR (European sales), while costs are largely in INR. Any sharp appreciation of the Indian rupee versus USD or EUR would reduce the INR value of exported revenues, compressing reported profitability.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aurobindo Pharma latest news 52-week high today is backed by strong fundamental performance and significant business catalysts. Ankit Jaiswal of Univest notes the fundamental story is compelling and the technical structure remains bullish. Kunal Singla observes that as long as the stock holds Rs 1,350 on weekly closes, the target zone of Rs 1,700 to 1,900 remains achievable. Investors should track the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index for sector-level signals alongside company-specific developments. Please consult a SEBI-registered investment advisor before making any investment decision.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Aurobindo Pharma live price and receive expert daily stock research.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Aurobindo_Pharma_Latest_News\"><\/span><strong>Frequently Asked Questions on Aurobindo Pharma Latest News<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Aurobindo_Pharma_latest_news_today\"><\/span><strong>What is Aurobindo Pharma latest news today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma latest news is that the stock hit a 52-week high of Rs 1,559, driven by Q4 FY26 revenue of Rs 8,751 crore (+4.42% YoY), US injectable growth of 17% YoY, the CDSCO approval of Bevqolva (biosimilar for cancer), and robust European market performance. The stock has surged 53% from its 52-week low of Rs 1,016.10.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Aurobindo_Pharma_at_52-week_high\"><\/span><strong>Why is Aurobindo Pharma at 52-week high?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma is at a 52-week high because of strong Q4 FY26 results, US injectable volume growth of 17% YoY, the CDSCO approval of Bevqolva biosimilar, and the ongoing Pen-G penicillin facility ramp-up that is expected to drive margin improvement in FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Bevqolva_approval_for_Aurobindo_Pharma\"><\/span><strong>What is the Bevqolva approval for Aurobindo Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bevqolva is a bevacizumab biosimilar developed by CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma. The CDSCO granted marketing authorisation for Bevqolva for cancer treatment. This is Aurobindo&#8217;s first large-molecule biosimilar approval in India, marking entry into the high-value oncology biosimilar market.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Aurobindo_Pharmas_valuation_versus_Nifty_Pharma_peers\"><\/span><strong>What is Aurobindo Pharma&#8217;s valuation versus Nifty Pharma peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma trades at a P\/E of 23.70x, significantly below the Nifty Pharma index median valuation of 35 to 40x. This makes it one of the more attractively valued large-cap pharma stocks in India. Market cap stands at approximately Rs 91,700 crore. Verify all data at nseindia.com before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Aurobindo_Pharmas_market_cap_and_valuation_at_the_52-week_high\"><\/span><strong>What is Aurobindo Pharma&#8217;s market cap and valuation at the 52-week high?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At the 52-week high of Rs 1,559, Aurobindo Pharma has a market capitalisation of approximately Rs ~91,700 crore and trades at a P\/E ratio of 23.70x. The 52-week low is Rs 1,016.10. All data should be verified at nseindia.com or bseindia.com before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Aurobindo_Pharma_a_buy_at_the_52-week_high\"><\/span><strong>Is Aurobindo Pharma a buy at the 52-week high?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Aurobindo Pharma is at a 52-week high, which means the stock is in price discovery territory without historical supply overhang. While this is technically a bullish signal, buying at 52-week highs carries short-term correction risk. Ankit Jaiswal of Univest recommends waiting for consolidation above Rs 1,350 before considering a fresh position. This is not investment advice. Consult a SEBI-registered financial advisor.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Latest Aurobindo Pharma latest news: Aurobindo Pharma hits 52-week high of Rs 1,559. Analyst views, next targets and key risks for investors.<\/p>\n","protected":false},"author":28,"featured_media":131051,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-131027","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782371940:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Aurobindo Pharma Latest News: Aurobindo Pharma Hits 52-Week High"],"rank_math_description":["Aurobindo Pharma latest news: Aurobindo Pharma (NSE: AUROPHARMA) hits 52-week high Rs 1,559. MCap Rs ~91,700 Cr, P\/E 23.70x. Analyst views and next targets."],"rank_math_focus_keyword":["Aurobindo Pharma Latest News"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["131051"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["21218"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Aurobindo-Pharma-Latest-News.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/131027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=131027"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/131027\/revisions"}],"predecessor-version":[{"id":131052,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/131027\/revisions\/131052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/131051"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=131027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=131027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=131027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}